Pharmacological Characterization and Modeling of the Binding Sites of Novel 1,3-Bis(pyridinylethynyl)benzenes as Metabotropic Glutamate Receptor 5-Selective Negative Allosteric Modulators

被引:32
|
作者
Molck, Christina [1 ]
Harpsoe, Kasper [2 ]
Gloriam, David E. [1 ]
Clausen, Rasmus P. [1 ]
Madsen, Ulf [1 ]
Pedersen, Lars O. [3 ]
Jimenez, Hermogenes N. [5 ]
Nielsen, Soren M. [4 ]
Mathiesen, Jesper M. [1 ]
Brauner-Osborne, Hans [1 ]
机构
[1] Univ Copenhagen, Dept Drug Design & Pharmacol, Fac Hlth & Med Sci, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen, NNF Ctr Prot Res, Fac Hlth & Med Sci, DK-2100 Copenhagen, Denmark
[3] H Lundbeck & Co AS, Dept Biol, Valby, Denmark
[4] H Lundbeck & Co AS, Dept Mol Pharmacol, Valby, Denmark
[5] Lundbeck Res USA, Dept Chem & Pharmacokinet Sci, Paramus, NJ USA
关键词
PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; STRUCTURAL INSIGHTS; MGLU5; RECEPTOR; SUBTYPE; ANTAGONIST; MECHANISM; GLUTAMATE-RECEPTOR-5; DISEASE; COMPLEX;
D O I
10.1124/mol.112.078808
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabotropic glutamate receptor subtype 5 (mGluR5) is a potential drug target in neurological and psychiatric disorders, and subtype-selective allosteric modulators have attracted much attention as potential drug candidates. In this study, the binding sites of three novel 2-methyl-6-(phenylethynyl)pyridine (MPEP)-derived negative allosteric modulators, 2-, 3-, and 4-BisPEB, have been characterized. 2-, 3-, and 4-BisPEB are 1,3-bis(pyridinylethynyl)-benzenes and differ only by the position of the nitrogen atoms in the pyridine rings. Despite their high structural similarity, 2-BisPEB [1,3-bis(pyridin-2-ylethynyl)-benzene, nitrogen atoms in ortho positions], with an IC50 value in the nanomolar range, is significantly more potent than the 3- and 4-pyridyl analogs. Mutational analysis, directed by a previously published mGluR5 homology model, was used to determine key residues for the ligand-receptor interactions that may explain the potency differences of 2-, 3-, and 4-BisPEB. Residues Ile651, Pro655, Tyr659, Asn747, Trp785, Phe788, Tyr792, Ser809, and Ala810 were found to have critical roles for the activity of one or more of the three BisPEBs and the reference compound MPEP. The mutagenesis data suggest that the higher potency of 2-BisPEB is due to hydrogen bonding to Ser809 because the S809A mutation made 2-BisPEB equipotent to 3- and 4-BisPEB (IC50, 1-2.5 mu M). The potency of MPEP was also greatly affected by S809A (52-fold), suggesting that a Ser809-mediated hydrogen bond is also a key interaction between MPEP and mGluR5. Potential binding modes of 2-, 3-, and 4-BisPEB obtained by molecular docking to the mGluR5 homology model provide a structural context for the reported major mutational effects.
引用
收藏
页码:929 / 937
页数:9
相关论文
共 50 条
  • [41] ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities
    Liu, Feng
    Grauer, Steve
    Kelley, Cody
    Navarra, Rachel
    Graf, Radka
    Zhang, Guoming
    Atkinson, Peter J.
    Popiolek, Michael
    Wantuch, Caitlin
    Khawaja, Xavier
    Smith, Deborah
    Olsen, Michael
    Kouranova, Evguenia
    Lai, Margaret
    Pruthi, Farhana
    Pulicicchio, Claudine
    Day, Mark
    Gilbert, Adam
    Pausch, Mark H.
    Brandon, Nicholas J.
    Beyer, Chad E.
    Comery, Tom A.
    Logue, Sheree
    Rosenzweig-Lipson, Sharon
    Marquis, Karen L.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03): : 827 - 839
  • [42] Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzonitrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications
    Galambos, Janos
    Bielik, Attila
    Krasavin, Mikhail
    Orgovan, Zoltan
    Domany, Gyorgy
    Nogradi, Katalin
    Wagner, Gabor
    Balogh, Gyorgy T.
    Beni, Zoltan
    Koti, Janos
    Szakacs, Zoltan
    Bobok, Amrita
    Kolok, Sandor
    Miko-Bakk, Monika L.
    Vastag, Monika
    Saghy, Katalin
    Laszy, Judit
    Halasz, Attila Sandor
    Balazs, Ottilia
    Gal, Krisztina
    Greiner, Istvan
    Szombathelyi, Zsolt
    Keseru, Gyorgy M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (06) : 2470 - 2484
  • [43] Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator
    Zhang, Lei
    Balan, Gayatri
    Barreiro, Gabriela
    Boscoe, Brian P.
    Chenard, Lois K.
    Cianfrogna, Julie
    Claffey, Michelle M.
    Chen, Laigao
    Coffman, Karen J.
    Drozda, Susan E.
    Dunetz, Joshua R.
    Fonseca, Kari R.
    Galatsis, Paul
    Grimwood, Sarah
    Lazzaro, John T.
    Mancuso, Jessica Y.
    Miller, Emily L.
    Reese, Matthew R.
    Rogers, Bruce N.
    Sakurada, Isao
    Skaddan, Marc
    Smith, Deborah L.
    Stepan, Antonia F.
    Trapa, Patrick
    Tuttle, Jamison B.
    Verhoest, Patrick R.
    Walker, Daniel P.
    Wright, Ann S.
    Zaleska, Margaret M.
    Zasadny, Kenneth
    Shaffer, Christopher L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (03) : 861 - 877
  • [44] Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics
    Garcia-Barrantes, Pedro M.
    Cho, Hyekyung P.
    Niswender, Colleen M.
    Byers, Frank W.
    Locuson, Charles W.
    Blobaum, Anna L.
    Xiang, Zixiu
    Rook, Jerri M.
    Conn, P. Jeffrey
    Lindsley, Craig W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (20) : 7959 - 7971
  • [45] Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a] benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1
    Kohara, A
    Toya, T
    Tamura, S
    Watabiki, T
    Nagakura, Y
    Shitaka, Y
    Hayashibe, S
    Kawabata, S
    Okada, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (01): : 163 - 169
  • [46] Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1H-Pyrazolo[4,3-b]pyridin-3-yl)amino)-benzo[d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4)
    Bollinger, Sean R.
    Engers, Darren W.
    Panarese, Joseph D.
    West, Mary
    Engers, Julie L.
    Loch, Matthew T.
    Rodriguez, Alice L.
    Blobaum, Anna L.
    Jones, Carrie K.
    Gray, Analisa Thompson
    Conn, P. Jeffrey
    Lindsley, Craig W.
    Niswender, Colleen M.
    Hopkins, Corey R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (01) : 342 - 358
  • [47] Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist:: In vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)
    Rorick-Kehn, Linda M.
    Johnson, Bryan G.
    Burkey, Jennifer L.
    Wright, Rebecca A.
    Calligaro, David O.
    Marek, Gerard J.
    Nisenbaum, Eric S.
    Catlow, John T.
    Kingston, Ann E.
    Giera, Deborah D.
    Herin, Marc F.
    Monn, James A.
    McKinzie, David L.
    Schoepp, Darryle D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (01): : 308 - 317
  • [48] Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC)
    Suzuki, Gentaroh
    Kimura, Toshifumi
    Satow, Akio
    Kaneko, Naoki
    Fukuda, Junko
    Hikichi, Hirohiko
    Sakai, Naoko
    Maehara, Shunsuke
    Kawagoe-Takaki, Hiroko
    Hata, Mikiko
    Azuma, Tomoko
    Ito, Satoru
    Kawamoto, Hiroshi
    Ohta, Hisashi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (03): : 1144 - 1153
  • [49] Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates
    Stepan, Antonia F.
    Claffey, Michelle M.
    Reese, Matthew R.
    Balan, Gayatri
    Barreiro, Gabriela
    Barricklow, Jason
    Bohanon, Michael J.
    Boscoe, Brian P.
    Cappon, Gregg D.
    Chenard, Lois K.
    Cianfrogna, Julie
    Chen, Laigao
    Coffman, Karen J.
    Drozda, Susan E.
    Dunetz, Joshua R.
    Ghosh, Somraj
    Hou, Xinjun
    Houle, Christopher
    Karki, Kapil
    Lazzaro, John T.
    Mancuso, Jessica Y.
    Marcek, John M.
    Miller, Emily L.
    Moen, Mark A.
    O'Neil, Steven
    Sakurada, Isao
    Skaddan, Marc
    Parikh, Vinod
    Smith, Deborah L.
    Trapa, Patrick
    Tuttle, Jamison B.
    Verhoest, Patrick R.
    Walker, Daniel P.
    Won, Annie
    Wright, Ann S.
    Whritenour, Jessica
    Zasadny, Kenneth
    Zaleska, Margaret M.
    Zhang, Lei
    Shaffer, Christopher L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (18) : 7764 - 7780
  • [50] Synthesis and Pharmacological Characterization of C4-Disubstituted Analogs of 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: Identification of a Potent, Selective Metabotropic Glutamate Receptor Agonist and Determination of Agonist-Bound Human mGlu2 and mGlu3 Amino Terminal Domain Structures
    Monn, James A.
    Prieto, Lourdes
    Taboada, Lorena
    Pedregal, Concepcion
    Hao, Junliang
    Reinhard, Matt R.
    Henry, Steven S.
    Goldsmith, Paul J.
    Beadle, Christopher D.
    Walton, Lesley
    Man, Teresa
    Rudyk, Helene
    Clark, Barry
    Tupper, David
    Baker, S. Richard
    Lamas, Carlos
    Montero, Carlos
    Marcos, Alicia
    Blanco, Jaime
    Bures, Mark
    Clawson, David K.
    Atwell, Shane
    Lu, Frances
    Wang, Jing
    Russell, Marijane
    Heinz, Beverly A.
    Wang, Xushan
    Carter, Joan H.
    Xiang, Chuanxi
    Catlow, John T.
    Swanson, Steven
    Sanger, Helen
    Broad, Lisa M.
    Johnson, Michael P.
    Knopp, Kelly L.
    Simmons, Rosa M. A.
    Johnson, Bryan G.
    Shaw, David B.
    Mc Kinzie, David L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) : 1776 - 1794